BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed/re...
Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia
25 Sep 2019
Continuous treatment versus fixed duration therapy: Using real-world evidence to...
Prof Evangelos Terpos, Prof Andrew Spencer and Dr Robert Rifkin
23 Sep 2019
Transitioning from bortezomib to ixazomib in patients with multiple myeloma
Dr Habte Yimer - Texas Oncology, Tyler, USA
23 Sep 2019
Evaluating treatment options for acute myeloid leukaemia
Dr Amanda Brahim - Memorial Healthcare System, Hollywood, FL, USA
26 Jul 2019
Recent advances in smouldering and relapsed or refractory multiple myeloma
Dr Jose Sandoval - Moffitt Cancer Center, Tampa, USA
26 Jul 2019
Use of platform studies for the evaluation of innovative combinations in solid t...
Dr Elizabeth Pease - AstraZeneca, UK
10 Jul 2019
Implementing national cancer control plans
Dr Eduardo Cazap and Dr Lisa Stevens
24 Jun 2019
Chemotherapy-free strategies in treating leukaemia
Prof Robin Foa - University of Rome, Rome, Italy
20 Jun 2019
Dasatinib-blinatumomab combination for the front-line treatment of adult Ph-posi...
Prof Robin Foa - University of Rome, Rome, Italy
20 Jun 2019
Dose escalation of REGN1979 in patients with relapsed and refractory B-NHL
Prof Max Topp - University of Würzburg, Würzburg, Germany
20 Jun 2019
CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-...
Dr Michaela Kotrova - Universitätsklinikum Schleswig-Holstein, Kiel, Germany
20 Jun 2019
ADMIRAL trial results: Gilteritinib versus salvage chemotherapy in patients with...
Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA
20 Jun 2019
